Moreover, clinic-genomic data revealed that HSP27 was more strongly involved in cancer prognosis than EGFR or AKT alone, and that overexpression of HSP27 potentiated negative effects in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.